Page 1 of 13 April – June 2015 Welcome to the 36TH Queensland Positive People (QPP) Treatment Update Newsletter The information, comments and editing in this newsletter do not necessarily represent the views of those providing primary HIV medical care....
More
Page 1 of 13 April – June 2015 Welcome to the 36TH Queensland Positive People (QPP) Treatment Update Newsletter The information, comments and editing in this newsletter do not necessarily represent the views of those providing primary HIV medical care. Always seek the advice of your doctor or clinical provider. 21 Manilla Street East Brisbane Qld 4169 - Post PO Box 7403 East Brisbane QLD 4169 Phone 07 3013 5555 - Toll Free 1800 636 241 (within QLD) Email info@qpp.org.au Gilead Requests Approval for Tenofovir Alafenamide (TAF) in new dual combination pill Gilead Sciences has requested U.S. Food and Drug Administration (FDA) approval of a new combination pill containing emtricitabine plus tenofovir alafenamide (together known as F/TAF). TAF is a new formulation that is easier on the kidneys and bones, according to a company press release. If approved, the new co-formulation could take the place of Truvada for HIV treatment, though its effectiveness for pre-exposure prophylaxis, or PrEP,
Less
